G Tambussi

Summary

Affiliation: San Raffaele Scientific Institute
Country: Italy

Publications

  1. ncbi Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997
    G Tambussi
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    J Biol Regul Homeost Agents 12:32-4. 1998
  2. ncbi Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy
    G Tambussi
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, 20137, Milan, Italy
    J Infect Dis 183:1476-84. 2001
  3. ncbi Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid
    G Tambussi
    Division of Infectious Diseases, San Raffaele Scientific Institute, 20127 Milano, Italy
    Clin Infect Dis 30:962-5. 2000
  4. ncbi The effect of HAART on humoral immune response in primary HIV-1 infected patients
    C Pastori
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Biol Regul Homeost Agents 16:9-17. 2002
  5. ncbi Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
    F B Lillo
    Laboratory of Virology, AIDS Center San Luigi, IRCCS Hospital San Raffaele, Milan, Italy
    AIDS 13:791-6. 1999
  6. doi Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2
    S Ghezzi
    Viral Pathogens and Biosafety Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    HIV Med 11:349-52. 2010
  7. ncbi Study on mutations and antiretroviral therapy (SMART): preliminary results
    N Gianotti
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 4:65-9. 1999
  8. ncbi The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs
    N Gianotti
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    J Biol Regul Homeost Agents 13:158-62. 1999
  9. ncbi HIV-1 DNA and RNA kinetics in primary HIV infection
    F Lillo
    Laboratory of Virology, Scientific Institute San Raffaele, Milan, Italy
    J Biol Regul Homeost Agents 16:49-52. 2002
  10. ncbi Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report
    B Capiluppi
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Biol Regul Homeost Agents 16:73-8. 2002

Detail Information

Publications25

  1. ncbi Prevalence of mutation associated to resistance with nucleoside analogues in a cohort of naïve HIV-1 positive subjects during the period 1984-1997
    G Tambussi
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    J Biol Regul Homeost Agents 12:32-4. 1998
    ..However, it is important to underline the trend and, in our opinion, further studies to better define the relevance of such phenomenon in the clinical practice must be performed...
  2. ncbi Efficacy of low-dose intermittent subcutaneous interleukin (IL)--2 in antiviral drug--experienced human immunodeficiency virus--infected persons with detectable virus load: a controlled study of 3 il-2 regimens with antiviral drug therapy
    G Tambussi
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, 20137, Milan, Italy
    J Infect Dis 183:1476-84. 2001
    ..Low doses of intermittent sc IL-2 induced a stable increase of peripheral CD4 cells that was indistinguishable from those associated with higher, less well-tolerated doses of IL-2...
  3. ncbi Neurological symptoms during primary human immunodeficiency virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid
    G Tambussi
    Division of Infectious Diseases, San Raffaele Scientific Institute, 20127 Milano, Italy
    Clin Infect Dis 30:962-5. 2000
    ..Moreover, early treatment including drugs with high levels of penetration in the CNS must be considered for patients with primary HIV infection...
  4. ncbi The effect of HAART on humoral immune response in primary HIV-1 infected patients
    C Pastori
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Biol Regul Homeost Agents 16:9-17. 2002
    ..These results may be relevant for understanding how HAART may elicit a strong protective responses and may be useful in developing new strategies designed to achieve a long term control of the HIV infection...
  5. ncbi Viral load and burden modification following early antiretroviral therapy of primary HIV-1 infection
    F B Lillo
    Laboratory of Virology, AIDS Center San Luigi, IRCCS Hospital San Raffaele, Milan, Italy
    AIDS 13:791-6. 1999
    ....
  6. doi Persistence of CCR5 usage among primary human immunodeficiency virus isolates of individuals receiving intermittent interleukin-2
    S Ghezzi
    Viral Pathogens and Biosafety Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    HIV Med 11:349-52. 2010
    ..To investigate the impact of intermittent interleukin-2 (IL-2) plus combination antiretroviral therapy (cART) on HIV-1 entry co-receptor use...
  7. ncbi Study on mutations and antiretroviral therapy (SMART): preliminary results
    N Gianotti
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    Antivir Ther 4:65-9. 1999
    ....
  8. ncbi The rationale for a study on HIV-1 reverse transcriptase mutations and outcome of antiretroviral therapy with two nucleoside analogs
    N Gianotti
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    J Biol Regul Homeost Agents 13:158-62. 1999
    ..In addition, this study could contribute to define the role of resistance assays in the management of HIV-1-infected patients...
  9. ncbi HIV-1 DNA and RNA kinetics in primary HIV infection
    F Lillo
    Laboratory of Virology, Scientific Institute San Raffaele, Milan, Italy
    J Biol Regul Homeost Agents 16:49-52. 2002
    ..To define the best method to measure low level viral replication, we determined the extent of HIV reservoir in 11 acutely infected patients and evaluated how it is renewed even during successful treatment...
  10. ncbi Implementation of an Italian multicentric care network for early HIV infection diagnosis: 1999-2001 report
    B Capiluppi
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Biol Regul Homeost Agents 16:73-8. 2002
    ..At the time of PHI diagnosis the case is reported to the coordinating centre and enrolled in the National Register which records all epidemiological, demographic and clinical information...
  11. ncbi In vivo administration of recombinant IL-2 to individuals infected by HIV down-modulates the binding and expression of the transcription factors ying-yang-1 and leader binding protein-1/late simian virus 40 factor
    C Bovolenta
    AIDS Immunophatogenesis Unit, DIBIT, Centro San Luigi, San Raffaele Scientific Institute, Milan, Italy
    J Immunol 163:6892-7. 1999
    ....
  12. ncbi Comparison of protease genotype and phenotype in HIV-1 infected patients exposed to more than one protease inhibitor
    N Gianotti
    Division of Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    J Biol Regul Homeost Agents 15:166-9. 2001
    ..Thus, more study of mutational patterns in heavily pretreated patients is warranted; in the mean time treatment choices might be optimized if phenotyping could integrate genotyping within this setting...
  13. doi Soluble endothelial protein C receptor (sEPCR) as an inflammatory biomarker in naive HIV-infected patients during ART
    S Chiappetta
    IRCCS San Raffaele Scientific Institute, Milan, Italy Università Vita Salute San Raffaele, Medicina e Chirurgia, Milan, Italy
    J Antimicrob Chemother 71:1627-31. 2016
    ..Multiple biomarkers have been studied as markers of disease. We wanted to test soluble endothelial protein C receptor (sEPCR) in an HIV setting...
  14. ncbi CCR5-reactive antibodies in seronegative partners of HIV-seropositive individuals down-modulate surface CCR5 in vivo and neutralize the infectivity of R5 strains of HIV-1 In vitro
    L Lopalco
    Department of Biological and Technological Research and Infectious Diseases Clinic, San Raffaele Scientific Institute, Milano, Italy
    J Immunol 164:3426-33. 2000
    ..These results contribute to clarifying the phenomenon of immunologic resistance to HIV and may have implications for the development of a protective vaccine...
  15. ncbi Acute self-limiting hepatitis C after possible sexual exposure: sequence analysis of the E-2 region of the infected patient and sexual partner
    G Morsica
    Infectious Diseases Department, San Raffaele Scientific Institute, Milan, Italy
    Scand J Infect Dis 33:116-20. 2001
    ..Our findings suggest that the infection was transmitted to the patient from her sexual partner. The resolution of acute hepatitis C in this case was probably related to the host rather than to intrinsic characteristics of the HCV genome...
  16. ncbi Selective enrichment of CD30-expressing cells within the blast region of lymphocytes from patients with primary HIV infection (PHI)
    P Biswas
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Biol Regul Homeost Agents 16:33-6. 2002
    ....
  17. doi Maraviroc 150 mg QD plus lopinavir/ritonavir, a NRTI-sparing regimen for HIV-infected naïve patients: 48-weeks final results
    S Nozza
    San Raffaele Scientific Institute, Milan, Italy
    J Int AIDS Soc 15:18232. 2012
    ....
  18. doi Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial
    M Ripa
    Universita Vita Salute San Raffaele, Department of Infectious and Tropical Diseases, Milan, Italy IRCCS Ospedale San Raffaele, Vaccine and Immunotherapy Research Centre, Milan, Italy IRCCS Ospedale San Raffaele, Department of Infectious and Tropical Diseases, Milan, Italy
    Clin Microbiol Infect 21:876.e1-4. 2015
    ..In conclusion, 48 weeks of cART during PHI showed significant benefits for both innate and adaptive immunity. ..
  19. ncbi Natural killer cell function in HIV-1 infected patients
    C Fortis
    Clinic of Infectious Diseases, San Raffaele Scientific Institute, Milan, Italy
    J Biol Regul Homeost Agents 16:30-2. 2002
    ....
  20. ncbi Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial
    W M El-Sadr
    Ann Intern Med 149:289-99. 2008
    ..Episodic use of antiretroviral therapy guided by CD4+ cell counts is inferior to continuous antiretroviral therapy...
  21. doi Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up
    Jens D Lundgren
    Copenhagen HIV Programme CHIP, Faculty of Health Sciences, University of Copenhagen, Panum Institute, 2200 Copenhagen N, Denmark
    J Infect Dis 197:1145-55. 2008
    ..Rates and predictors of opportunistic disease or death (OD/death) and the relative risk (RR) in DC versus VS groups according to the latest CD4+ cell count and HIV RNA level are reported...
  22. ncbi Evaluation of Subcutaneous Proleukin (interleukin-2) in a Randomized International Trial (ESPRIT): geographical and gender differences in the baseline characteristics of participants
    S L Pett
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    HIV Clin Trials 7:70-85. 2006
    ....
  23. doi Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study
    Sean Emery
    Therapeutic and Vaccine Research Program, National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria St, Sydney, NSW 2010, Australia
    J Infect Dis 197:1133-44. 2008
    ..In the DC group, participants started ART when the CD4+ cell count was <250 cells/microL. Clinical outcomes in participants not receiving ART at entry inform the early use of ART...
  24. ncbi Expression and activation of a C-terminal truncated isoform of STAT5 (STAT5 Delta) following interleukin 2 administration or AZT monotherapy in HIV-infected individuals
    C Bovolenta
    AIDS Immunopathogenesis Unit, DIBIT, 20132 Milano, Italy
    Clin Immunol 99:75-81. 2001
    ..We provide evidence that both therapeutic interventions enhanced the expression and activation of the C-terminal truncated isoform of STAT5 (STAT5 Delta) in vivo...
  25. ncbi Molecular and phylogenetic characterization of HIV variants in Italian primary HIV infections (PHI): identification of non-B subtype variants
    L Buonaguro
    Division of Viral Oncology and AIDS Reference Center, Istituto Nazionale dei Tumori Fondazione G Pascale, Naples, Italy
    J Biol Regul Homeost Agents 16:44-8. 2002
    ....